An Open-label, Multicenter, Phase 1b Study of JNJ-63723283, a PD-1 Inhibitor, Administered in Combination With Apalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer
Phase of Trial: Phase I
Latest Information Update: 03 Feb 2019
At a glance
- Drugs Apalutamide (Primary) ; Cetrelimab (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Janssen Research & Development
- 06 Dec 2018 Planned End Date changed from 9 Jun 2020 to 29 Jan 2021.
- 03 Jul 2018 Status changed from not yet recruiting to recruiting.
- 14 Jun 2018 New trial record